Troy Ignelzi

Troy has nearly two decades of financial leadership experience in the biotech and pharmaceuticals sectors. Over the course of his career, Troy has raised over $4B in capital for life science companies. He focuses on providing valuable financial and business development counsel across all therapeutic areas in our portfolio. Troy is currently the Chief Financial Officer for Rapport Therapeutics, a Sofinnova portfolio company.

Before Rapport Therapeutics, Troy was Chief Financial Officer at Karuna Therapeutics, where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings. Prior to Karuna, Troy served as Chief Financial Officer at two other companies, Juventas Therapeutics and scPharmaceuticals. He has a long track record of experience in the sector, having started at Eli Lilly and then moving on to roles of increasing responsibility at companies including Esperion Therapeutics and the former Insys Therapeutics. Previously, Troy served on the board of CinCor Pharma, Inc., where he advised on the company’s sale to AstraZeneca in early 2023. He currently serves on the boards of Vedanta Biosciences and Abivax (ABVX).

Troy earned his B.S. in accounting from Ferris State University.